Section Arrow
RCUS.NYSE
- Arcus Biosciences
Quotes are at least 15-min delayed:2024/06/24 08:22 EDT
Last
 16.35
+0.16 (+0.99%)
Day High 
16.815 
Prev. Close
16.19 
1-M High
17.56 
Volume 
3.75M 
Bid
15.66
Ask
16.5
Day Low
16.01 
Open
16.42 
1-M Low
14.69 
Market Cap 
1.47B 
Currency USD 
P/E -- 
%Yield
10-SMA 16.13 
20-SMA 15.97 
50-SMA 16 
52-W High 25.47 
52-W Low 12.95 
Exchange NYSE 
Valuation Estimation
EPS (Current/Estimated)
-3.11/-2.28
Enterprise Value
1.59B
Balance Sheet
Book Value Per Share
7.77
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
117.00M
Operating Revenue Per Share
1.32
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
MBIOMustang Bio0.5594-0.0011-0.20%-- 
DNAGinkgo Bioworks Holdings0.4244+0.0157+3.84%-- 
KTRAKintara Therapeutics0.2472-0.0277-10.08%-- 
BMRNBioMarin Pharmaceutical83.72-0.99-1.17%79.92PE
QLGNQualigen Therapeutics0.222+0.0449+25.35%-- 
Quotes are at least 15-min delayed:2024/06/24 08:22 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.